Stage (next event)
Quarterly Sales (Approved)
Catalyst Info & Data Links
TITLE: HETLIOZ® (tasimelteon) - Quarterly Sales
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
January 2021 (Est)
10-28-2020 Third Quarter 2020 Financial Results
08-05-2020 Second Quarter 2020 Financial Results
05-06-2020 First Quarter 2020 Financial Results
11-06-2019 Third Quarter 2019 Financial Results
07-31-2019 Second Quarter 2019 Financial Results
05-01-2019 First Quarter 2019 Financial Results
11-07-2018 Third Quarter 2018 Financial Results
08-01-2018 Second Quarter 2018 Financial Results
05-02-2018 First Quarter 2018 Financial Results
2015: Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. The Lancet, 386(10005), 1754-1764.
2015: Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology, 91, 142-147.
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
The precise mechanism by which tasimelteon exerts its therapeutic effect in patients with Non- 24 is not known. Tasimelteon is an agonist at melatonin MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms (Learn more pg.6)
HETLIOZ® (tasimelteon) - The first and only FDA-approved treatment for Non-24-Hour Sleep-Wake Disorder (Non-24).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post